Target intelligence / Profile preview

FimH adhesin (FimH)

Target
FimH
Molecular classification
Adhesin, Lectin, Bacterial surface protein
01

Overview

FimH is a 30 kDa lectin-like adhesin located at the distal tip of type 1 fimbriae in uropathogenic Escherichia coli (UPEC) (UniProt P08191). It is the primary mediator of bacterial attachment to the bladder epithelium (urothelium) by specifically recognizing and binding to terminal mannose residues on glycoproteins like uroplakin Ia. This adhesion is a prerequisite for colonization, biofilm formation, and subsequent invasion of the host cells, which leads to the development of urinary tract infections (UTIs). The binding mechanism involves a catch-bond behavior, where tensile force increases the affinity of FimH for its ligand, helping the bacteria withstand the flow of urine. Because FimH-mediated binding is crucial for pathogenesis, it has become a major target for anti-adhesion therapies. Small-molecule FimH antagonists, such as mannosides like GSK3882347 and Sibofimloc (EB8018), are designed to competitively occupy the mannose-binding pocket of FimH. These drugs effectively prevent bacterial attachment, allowing the pathogen to be cleared naturally by urine flow without the use of traditional bactericidal antibiotics. This approach is particularly promising for treating recurrent UTIs and reducing the selection pressure for antibiotic resistance.

Other names
Type 1 pilus tip adhesinMannose-binding adhesinUropathogenic E. coli adhesinFimH protein
02

Mechanism of action

Competitive inhibition of the FimH lectin domain, preventing its binding to mannosylated uroplakin receptors on the host urothelium.

03

Biological functions

Bacterial adhesionCell colonizationBiofilm formationHost-pathogen interaction
04

Disease associations

Urinary tract infectionCystitisPyelonephritisUrosepsisInflammatory bowel disease
05

Safety considerations

Potential alteration of the commensal gut microbiomeLow oral bioavailability of certain mannoside derivativesRisk of selecting for non-fimbriated bacterial variants
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

Bacterial colony forming units (CFU) in urineFimH gene expression levels in clinical isolatesUrinary inflammatory cytokines (e.g., IL-6, IL-8)

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on FimH adhesin (FimH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FimH adhesin (FimH).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call